EMAIL THIS PAGE TO A FRIEND

Chemico-biological interactions

Pretreatment with turmeric modulates the inhibitory influence of cisplatin and paclitaxel on CYP2E1 and CYP3A1/2 in isolated rat hepatic microsomes.


PMID 24882083

Abstract

Previous animal studies have shown that turmeric can significantly modulate the activity of several drug metabolizing enzymes, this may dramatically affect the bioavailability of several drugs resulting in over dose or less therapeutic effects. This study was directed to evaluate the inhibitory effects of cisplatin and paclitaxel on two CYP450 enzymes namely CYP2E1 and CYP3A1/2 in hepatic microsomes isolated from normal and turmeric pretreated rats. Cisplatin and paclitaxel were added by different concentrations to hepatic microsomes isolated from untreated and turmeric (100 mg/kg/day) pretreated rats for 15 days after receiving pyrazole or dexamethasone for induction of CYP2E1 and CYP3A1/2 respectively. The kinetic potency of these drugs as CYP inhibitors was determined by analysis of Lineweaver-Burk plot. Addition of cisplatin or paclitaxel by (10, 50 and 100 μM) to hepatic microsomes from normal or turmeric pretreated rats caused a concentration dependent inhibition of CYP2E1, with an evidence of less inhibition in turmeric pretreated microsomes particularly at higher concentration. Both drugs at 100 μM displayed a mixed type of inhibition of CYP2E1 in normal or turmeric pretreated microsomes where paclitaxel was the most potent inhibitor. Cisplatin (10, 50 and 100 μM) caused a concentration dependant inhibition of CYP3A1/2 that was enhanced by turmeric pretreatment. The inhibition of CYP3A1/2 by cisplatin (100 μM) was in non-competitive manner with a smaller Ki value in turmeric pretreated microsomes. The inhibitory influence of paclitaxel (10, 50 and 100 μM) on CYP3A1/2 decreased with increasing the drug concentration and this inhibition was augmented by turmeric pretreatment. Interestingly, the inhibition of this enzyme by paclitaxel (10 μM) was switched from mixed type in normal microsomes to competitive manner in turmeric pretreated ones with a marked reduction of Ki values reflecting greater inhibitory influence of paclitaxel on CYP3A1/2 by turmeric pretreatment. In conclusion, turmeric pretreatment attenuated the inhibitory influence of cisplatin and paclitaxel on CYP2E1 activity and magnified their inhibition on CYP3A1/2, thus the use of turmeric with drugs or other medications should raise concern for drugs-herb interactions.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

1048
4-Nitrophenol, spectrophotometric grade
C6H5NO3
35836
4-Nitrophenol, PESTANAL®, analytical standard
C6H5NO3
241326
4-Nitrophenol, ReagentPlus®, ≥99%
C6H5NO3
48549
4-Nitrophenol, Reference Material
C6H5NO3
PHR1150
4-NITROPHENOL (Acetaminophen Related Compound F)(Paracetamol Impurity F), Pharmaceutical Secondary Standard; Certified Reference Material
C6H5NO3
N7660
4-Nitrophenol solution, 10 mM
C6H5NO3
40056
4-Nitrophenol solution, certified reference material, 5000 μg/mL in methanol
C6H5NO3
43575
4-Nitrophenol solution, stock solution, for mass spectrometry
C6H5NO3
49053
4-Nitrophenol solution, working solution, for mass spectrometry
C6H5NO3
E6376
Erythromycin, potency: ≥850 μg per mg
C37H67NO13
E5389
Erythromycin, BioReagent, suitable for cell culture
C37H67NO13
45674
Erythromycin, tested according to Ph.Eur.
C37H67NO13
PHR1039
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
C37H67NO13
E1300000
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
C37H67NO13
1242000
Erythromycin, United States Pharmacopeia (USP) Reference Standard
C37H67NO13
E0774
Erythromycin, meets USP testing specifications
C37H67NO13
E4514
Erythromycin, plant cell culture tested, ~98%
C37H67NO13
45703
Erythromycin standard solution, 1 mg/mL in H2O
C37H67NO13
82620
Pyrazole, purum, ≥98.0% (GC)
C3H4N2
P56607
Pyrazole, 98%
C3H4N2